Allergan Urgently Seeks FDA Guidance To Unblock Vraylar sNDA Review
Executive Summary
In its initial assessment of Allergan's sNDA for Vraylar, the FDA has found the application - for treating negative symptoms associated with schizophrenia – wanting, and thus says it doesn't merit a full review.
You may also be interested in...
Allergan Hopes To Add Bipolar Depression To Vraylar's Label
With Phase III success in bipolar depression, Allergan plans an sNDA in 2018 to add that indication to the atypical antipsychotic's label, which includes schizophrenia and bipolar mixed or manic episodes.
Allergan Readies Cost Cuts As Restasis Generics Approach
Allergan is working on a plan to reduce costs now that Restasis generics could hit the US market in 2018, but the company said sales growth for other drugs coupled with new product launches will boost revenue even if the dry eye drug loses its blockbuster status.
Allergan/Richter’s Antipsychotic Vraylar Offers New Mechanism Of Action
Schizophrenia and bipolar disorder treatment will launch in first quarter of 2016.